Neurology
Idiopathic Parkinson's Disease
0
Pipeline Programs↗
4
Active Trials↗
11
Companies Involved↗
Idiopathic Parkinson's Disease is an early-stage landscape with 0 programs across 11 companies. The most active players are UCB, Boehringer Ingelheim, Newron Pharmaceuticals SPA.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
40
clinical trials
Completed30 · 75%
Terminated4 · 10%
Recruiting2 · 5%
Withdrawn1 · 3%
Unknown status1 · 3%
Not yet recruiting1 · 3%
Other1 · 3%
Clinical Trials
Trial Activity
40 trials
Single-center Study of Gustation in Idiopathic Parkinson's Disease and Lewy Body Disease Using Gustatory Evoked Potential Analysis
Recruiting·—·N/A·NCT06439355·66 enrolled
Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease
Not yet recruiting·TTaiwan Mitochondrion Applied Technology Co., Ltd.·Phase 1·NCT05094011·9 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)